Company intelligence / Profile preview

Incyclix Bio

Research Triangle Park, North Carolina, United Statesincyclixbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

INX-315, the company's lead CDK2 inhibitor, has received FDA Fast Track designation for treating CCNE1-amplified platinum-resistant/refractory ovarian cancer. It is currently in a Phase 1/2 clinical trial evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with recurrent advanced/metastatic cancer.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

INX-315

Beyond the preview

Go deeper on Incyclix Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Incyclix Bio.

Explore the full profile